309 related articles for article (PubMed ID: 20528905)
1. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.
Sancho JM; Orfao A; Quijano S; García O; Panizo C; Pérez-Ceballos E; Deben G; Salar A; González-Barca E; Alonso N; García-Vela JA; Capote J; Peñalver FJ; Provencio M; Arias J; Plaza J; Caballero D; Morado M; Feliu E; Ribera JM;
Eur J Haematol; 2010 Oct; 85(4):321-8. PubMed ID: 20528905
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin's Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease.
Huang S; Jin L; Yang J; Duan Y; Zhang M; Zhou C; Zhang YH
Technol Cancer Res Treat; 2021; 20():15330338211016372. PubMed ID: 34060372
[TBL] [Abstract][Full Text] [Related]
3. [Clinical diagnostic significance of cerebrospinal fluid detection with flow cytometry in children acute lymphoblastic leukemia accompanied by central nervous system leukemia].
Yang WY; Wang HJ; Chen YM; Chen XJ; Zou Y; Guo Y; Wang SC; Liu TF; Zhu XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):38-42. PubMed ID: 22391161
[TBL] [Abstract][Full Text] [Related]
4. The risk of CNS involvement in aggressive lymphomas in the rituximab era.
Benevolo G; Chiappella A; Vitolo U
Expert Rev Hematol; 2013 Dec; 6(6):643-52. PubMed ID: 24168678
[TBL] [Abstract][Full Text] [Related]
5. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.
Quijano S; López A; Manuel Sancho J; Panizo C; Debén G; Castilla C; Antonio García-Vela J; Salar A; Alonso-Vence N; González-Barca E; Peñalver FJ; Plaza-Villa J; Morado M; García-Marco J; Arias J; Briones J; Ferrer S; Capote J; Nicolás C; Orfao A;
J Clin Oncol; 2009 Mar; 27(9):1462-9. PubMed ID: 19224854
[TBL] [Abstract][Full Text] [Related]
6. Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas.
Di Noto R; Scalia G; Abate G; Gorrese M; Pascariello C; Raia M; Morabito P; Capone F; Pardo CL; Mirabelli P; Mariotti E; Del Vecchio L
Leuk Res; 2008 Aug; 32(8):1196-9. PubMed ID: 18262645
[TBL] [Abstract][Full Text] [Related]
7. Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse.
Martínez-Laperche C; Gómez-García AM; Lassaletta Á; Moscardó C; Vivanco JL; Molina J; Fuster JL; Couselo JM; de Toledo JS; Bureo E; Madero L; Ramírez M
Am J Hematol; 2013 May; 88(5):359-64. PubMed ID: 23468276
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma.
Alvarez R; Dupuis J; Plonquet A; Christov C; Copie-Bergman C; Hemery F; Gaillard I; El Gnaoui T; Kuhnowski F; Bedoui M; Belhadj K; Brugières P; Haioun C
Ann Oncol; 2012 May; 23(5):1274-1279. PubMed ID: 21965472
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
10. Optimization of CSF biological investigations for CNS lymphoma diagnosis.
Armand M; Costopoulos M; Osman J; Tarfi S; Houillier C; Choquet S; Agnelo H; Bonnemye P; Ronez E; Settegrana C; Soussain C; Hoang-Xuan K; Le Garff-Tavernier M; Davi F
Am J Hematol; 2019 Oct; 94(10):1123-1131. PubMed ID: 31328307
[TBL] [Abstract][Full Text] [Related]
11. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination.
Benevolo G; Stacchini A; Spina M; Ferreri AJ; Arras M; Bellio L; Botto B; Bulian P; Cantonetti M; Depaoli L; Di Renzo N; Di Rocco A; Evangelista A; Franceschetti S; Godio L; Mannelli F; Pavone V; Pioltelli P; Vitolo U; Pogliani EM;
Blood; 2012 Oct; 120(16):3222-8. PubMed ID: 22927246
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometric analysis of cerebrospinal fluid in adult patients with acute lymphoblastic leukemia during follow-up.
Gong X; Lin D; Wang H; Wang Y; Liu B; Wei H; Zhou C; Liu K; Wei S; Gong B; Zhang G; Liu Y; Zhao X; Li Y; Gu R; Qiu S; Mi Y; Wang J
Eur J Haematol; 2018 Mar; 100(3):279-285. PubMed ID: 29240262
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology.
Márky I; Björk O; Forestier E; Jónsson OG; Perkkiö M; Schmiegelow K; Storm-Mathiesen I; Gustafsson G;
J Pediatr Hematol Oncol; 2004 Sep; 26(9):555-60. PubMed ID: 15342981
[TBL] [Abstract][Full Text] [Related]
14. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.
Tomita N; Yokoyama M; Yamamoto W; Watanabe R; Shimazu Y; Masaki Y; Tsunoda S; Hashimoto C; Murayama K; Yano T; Okamoto R; Kikuchi A; Tamura K; Sato K; Sunami K; Shibayama H; Takimoto R; Ohshima R; Hatta Y; Moriuchi Y; Kinoshita T; Yamamoto M; Numata A; Ishigatsubo Y; Takeuchi K
Cancer Sci; 2012 Feb; 103(2):245-51. PubMed ID: 22044593
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patients.
Nachmias B; Sandler V; Slyusarevsky E; Pogrebijski G; Kritchevsky S; Ben-Yehuda D; Goldschmidt N; Gatt ME
Ann Hematol; 2019 Nov; 98(11):2561-2567. PubMed ID: 31515574
[TBL] [Abstract][Full Text] [Related]
18. High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma.
Del Principe MI; Buccisano F; Cefalo M; Maurillo L; Di Caprio L; Di Piazza F; Sarlo C; De Angelis G; Irno Consalvo M; Fraboni D; De Santis G; Ditto C; Postorino M; Sconocchia G; Del Poeta G; Amadori S; Venditti A
Ann Hematol; 2014 Sep; 93(9):1509-13. PubMed ID: 24752416
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.
Bierman P; Giglio P
Hematol Oncol Clin North Am; 2005 Aug; 19(4):597-609, v. PubMed ID: 16083825
[TBL] [Abstract][Full Text] [Related]
20. CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma.
Sandlund JT; Murphy SB; Santana VM; Behm F; Jones D; Berard CW; Furman WL; Ribeiro R; Crist WM; Greenwald C; Chen G; Walter A; Pui CH
J Clin Oncol; 2000 Aug; 18(16):3018-24. PubMed ID: 10944136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
